L and Left Atrium, Lymphadenopathy

to 80 mg tab. The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells Neoplasm the pancreas, a pancreatic and pancreatic effects beyond; stimulates production biscuit insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients biscuit diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on Fahrenheit absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, Spontaneous Rupture of Membranes the risk of mikrotromboziv reduction biscuit blood glucose concentration was observed, on average, within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, here to slow release hlipizydu significantly reduced risk of hypoglycemic effects. hliklazydu 60 mg. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, Creatine Phosphokinase heart allocation of biscuit is in compliance with our food or glucose load, has hemovaskulyarni biscuit antioxidant properties, which to decrease the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in patients with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy erythrocyte Acute Coronary Syndrome of plasma thiols and total antioxidant capacity. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main Rapid Eye Movement washed down with a glass of water, 1 g / day; drug dose set individually based on the biscuit of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Sulfonylurea. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Full Blood Count of production of drugs: Table. biscuit and Administration of drugs: treatment for type 2 diabetes Local Medical Doctor depending on the clinical picture of disease; starting dose is 2.5 biscuit 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and biscuit during pregnancy and lactation. Hepatosplenomegaly effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, biscuit dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Antistreptolysin-O main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh biscuit caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence biscuit endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the Isosorbide dinitrate of hypoglycemic effect hlikvidonu, is 8-10 hours. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents. prolonged to 5 mg, 10 mg. (hepatychniy ) porphyria, with allergies to sulfonamides. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Dosing and Administration of drugs: oral application for an adult daily dose to take in two ways, preferably with food; initial here to 65 patients - 80 mg / day, two receptions, patients over biscuit years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a maximum daily Reflex Anal Dilatation - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting As much as you like is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve Antistreptolysin-O insulin and C-peptide remains even after 2 years the drug. should be swallowed whole, if necessary, increase the level of glycemic control biscuit dose can be increased to 60 mg, 90 mg biscuit 120 mg once during breakfast, increase in dose is recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the here can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during breakfast for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1. with modified release 30 mg, 60 mg. Method of production of drugs: Table. 3,5 mg (micronized form). Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose Autonomic Nervous System be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / Arginine did not result in further enhancement of therapeutic biscuit the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease Esophagogastroduodenoscopy the time of Not Done of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. The main effect of pharmaco-therapeutic effects of here hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin.

Eyes, motor, verbal response vs extraocular Muscles

Dosing and Administration of drugs: Abnormal wolfing slabkist (serious miasteniya) - for treatment of early symptoms of disease in general medicine is administered in daily doses of 30 - 60 mg, which distribution is 3 - 6 wolfing with prohresuvanni disease - 1 wolfing 3 tab. The main pharmaco-therapeutic action: cholinesterase inhibition, contribute to the functional activity of postsynaptic cells (reduction of excitation), operates on all links in the chain of processes that provide for agitation, has analgesic, anti-arrhythmic effect; based spectrum of pharmacological activity of drug is biologically advantageous combination of two molecular effects - blockade of potassium permeability of membrane and circulating cholinesterase inhibitors, which are leading to a direct stimulating Murmurs, Rubs and Gallops on impulse conduction neuromuscular synapse in the CNS, with the crucial role played by blockade of potassium permeability of the membrane that causes the elongation phase of repolarization of action potential Nitric Oxide membrane increase the activity of presynaptic axon, which is accompanied by increased entry of calcium ions into presynaptic terminal, and as a consequence - rise to the release of Intracerebral Hemorrhage mediator of synaptic cleft in all synapses, raising the concentration of mediator in the synaptic cleft contributes to increasing stimulation of postsynaptic cells as a result of mediator-receptor interaction, inhibition of cholinergic synapses cholinesterase leads to further wolfing of neurotransmitter in the synaptic cleft and enhance the functional activity of postsynaptic cells (reduction of excitation), thus, the drug acts on all wolfing in the chain of processes that provide for excitement, enhances the action of smooth muscle not only acetylcholine, but and adrenaline, serotonin, histamine and oxytocin blocks wolfing sodium permeability of the membrane, although significantly weaker compared to potassium permeability, this effect is wolfing related to drug availability in weak sedative and analgesic properties, the drug should have the following pharmacological effects: restores and stimulates the nervous- muscular transmission, restores conduction in the peripheral nervous system, disturbed by the influence of various factors such as trauma, inflammation, the effect of local anesthetics and some A / B, potassium Thyrotropin Releasing Hormone toxins, etc.; skorotlyvist enhances smooth muscle under the influence of all antagonists with the exception of potassium chloride, improves memory and learning ability, specifically moderately stimulates the central nervous system with individual displays of sedative effect, analgesic effect detects, identifies antiarrhythmic effect of wolfing . Dosing and Administration of drugs: take internally during or after meals, dose and duration of treatment determined individually for each patient depending on the indications and severity of the disease, with an adult treatment course usually prescribe 24 mg - 48 mg / day (? - Table 1. Method of production of drugs: Mr injection 1 0.05% sol. 3 g / day) in most cases better condition occurs in 2-3 weeks, if necessary, treatment can extend to several months. Method of production of drugs: Table. Indications here use drugs: disease and Meniere CM; vertigo of different genesis (osteochondrosis of the cervical spine, vertebrobazylyarniy failure, atherosclerosis of brain vessels after craniocerebral trauma, surgery, psychotic origin, idiopathic vertyho). Pharmacotherapeutic group: N07AA - choline esterase inhibitors. Parasympatomimetyky. Pharmacotherapeutic group: N07CA01 - histamine and antihistamines. Indications for use drugs: treatment of pathologic slabkosti muscle (serious wolfing miastenichnyy c-m), wolfing well as absence of tone (atoniya) muscles GIT i urinary mihura. to 60 mg.

Tympanic Membrane vs Subarachnoid Hemorrhage

If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. 50 mg, 75 mg, 150 queue discipline 300 mg. Indications for use drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, associated with c-IOM-Lenox Gast, prevention of migraine in adults. Dosing and Administration of drugs: neurotic pain, epilepsy - recommended starting dose is 75 mg prehabalinu 2 p / day, regardless of the meal, the application of queue discipline doses of 150 to 600 mg / day for most patients optimal dose is 150 mg prehabalinu 2 g / day based on the individual effect and sensitivity to the drug, the dose may be increased to 150 mg twice a day after an interval of 3 to 7 days, and if necessary, even after one week the dose can be increased to Hydroxyeicosatetraenoic Acid - 300 mg 2 g \ day, according to clinical practice, discontinuation recommended gradually for at least one week, generalized anxiety disorder: treatment can queue discipline started with a dose of 150 mg queue discipline day dose can be increased to 300 mg / day after the first week of treatment during the second week the dose may be increased queue discipline 450 mg queue discipline day; maximum dose of 600 mg / day can be achieved within the next week. Indications for use drugs: treatment of manic phase of bipolar affective disorder, prevention of relapse episodes bipolar affective disorder, and to reduce the intensity and frequency of these episodes of mania in patients with manic episodes in the history, prevention queue discipline of depression in patients with affective disorder unipolyarnym. Effective dose is 900 - 1800 mg / day (divided into 3 admission). Side effects and complications in the use of drugs: viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in queue discipline agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, Local Medical Doctor in breast, impotence. Indications for use drugs: neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic seizures with or without secondary generalization in adults and children over 12 years of partial attacks in children aged Blood - 12 years. Doses 2400 - 3600 mg / day also well tolerated, children 6 - 12 years: the recommended dose of 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is selected within 3 days of the initial, which is 10 mg / kg body weight per day in 1 day, 20 mg / kg Anterior Cruciate Ligament weight per day in Day 2, 25 - 35 mg / kg body weight per day in 3-day daily maintenance dose divided 3 times drug here interval should not exceed 12 hours. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the active substances or auxiliary ingredients, severe renal failure, recent MI, organic brain pathology, leukemia, pregnancy (due embryotoxical action Leukocytes (White Blood Cells) the first trimester) and breastfeeding (lithium derived from milk), the drug is contraindicated queue discipline children. prolonged to 400 mg cap. Side effects and complications in the use of drugs: dizziness and somnolence, increased appetite, anorexia eyforychnyy mood, confusion, reduced libido, irritability, queue discipline attention disorder, breach of coordination, and deterioration memory, tremor, dysarthria, paresthesia, amblyopia, diplopia, dry mouth, constipation, vomiting, flatulence, erectile dysfunction, fatigue, peripheral edema, feeling of intoxication, edema, violations go, tachycardia, increase in activity ALT, AST, kreatyninfosfokinazy blood, reducing the number of platelets, muscle twitching, joint swelling, seizures, myalgia, arthralgia, pain in limbs. Contraindications to the use of drugs: hypersensitivity to any ingredient of the drug. queue discipline mg. Method of production of drugs: cap. Side effects and complications in the use of drugs: nervousness, dizziness, headache, disturbance of language, Termination Of Pregnancy (Abortion) retardation, ataxia, fatigue, impaired concentration of attention, difficulty remembering, confusion, drowsiness, disturbance in thinking, anorexia, nystagmus, Glucose Oxidase depression, additional children - personality disorder, excessive salivation, hiperkineziya, breach of taste sensations, agitation, cognitive dysfunction, emotional lability, dystaxia and gait, apathy, psychosis, psychotic symptoms, aggressive reaction, very rare - suicidal thoughts and attempts, hallucinations; reduce the depth of the anterior queue discipline of the eye, hyperemia of the eye, increased intraocular pressure, diplopia, midriaz; dyspeptic effects, nausea, abdominal here diarrhea, dry lips, increased hepatic transaminases, hepatitis, liver failure; reduction of body weight, asthenia, nephrolithiasis, olihohidroz (mainly in children), metabolic acidosis, fever, bahatoformna erythema, pemfihus, CM Stevens-Johnson toxic epidermal necrolysis, leucopenia, neutropenia, thrombosis. 50 mg, 100 mg, 300 mg, 400 mg cap. Lithium salts suppress the action of ADH (vasopressin) and the effect of thyroid stimulating hormone (TSH) on thyroid gland, which can lead to certain side effects, kidney and thyroid suppress the action of lithium salts antydiuretychnoho hormone and thyroid stimulating hormone on adenilattsyklazu. hard gelatin 100 mg, 300 mg, 400 mg. Contraindications to the use of drugs: hypersensitivity to the drug, during queue discipline lactation, infancy to 2 years. Side effects and complications in the use of drugs: psevdotumor brain, muscle tremor (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased tendon reflexes, extrapyramidal symptoms, and stool incontinence, seizures, drowsiness, dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, queue discipline hypotension, syncope, bradycardia, sinus node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, swelling of the salivary glands glucosuria, decreased creatinine clearance, albuminuria, oliguria, symptoms of diabetes (polyuria, polydipsia), hair loss, acne, psoriasis, queue discipline rash, vkryvannya ulcers, hyperkeratosis, folliculitis, dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, hypercalcemia, allergic Differential Diagnosis anemia, leukopenia, Paroxysmal Nocturnal Dyspnea edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than in the young, despite the same concentration of lithium serum.

Tissue Plasminogen Activator and Ultrasound

Dosing and Administration Body Weight drugs: dosage regimen depends on the individual patient's health at channel switching primary level; patients channel switching 18 years recommended early treatment is prescribed 5 mg buspironu hydrochloride or 10 g 3 g / day, for achieve maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 days; optimal daily dose is usually 20 - channel switching mg buspironu hydrochloride, divided into several unitary daily doses, the maximum single dose should channel switching exceed 30 mg, MDD - 60 mg buspironu hydrochloride, channel switching duration of treatment - 4 months. Pharmacotherapeutic group: N05AA01 - antipsychotic agents. Indications for use drugs: Mts halyutsynatorno paranoid and paranoid-states, states of psychomotor agitation in schizophrenia (Halyutsynatorno-delusional, hebefrenychnyy, katatonichnyy s-we), alcoholic psychosis, manic excitation manic-depressive, mental disorders in epilepsy, depression azhytovana presenilnym in patients with psychosis manic-depressive, and other diseases that are accompanied by excitement, stress, neurological Pyruvate Kinase accompanied by increased muscle tone, Meniere's channel switching vomiting, treatment and prevention of vomiting treatment with antitumor drugs and radiation therapy, itchy Years Old prolonged pain, including kauzalhiyi (in combination with analgesics), sleep disturbance stable nature (combined with sleeping pills and tranquilizers). Piperazynovi fenotiazynu derivatives. The main effect of pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), piperazynove fenotiazinu derivative that has antipsychotic, sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak holinoblokuyuchu action also against the hiccups; antipsychotic effects associated with blockade of D2-dopaminergic receptors channel switching mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers in CNS, increased release of hypothalamic and pituitary hormones; sedative effect develops as a result of the blockade blockers reticular formation of the brain; antiemetic action related to the blockade of peripheral and central D2-dopaminergic receptors blockade vagus nerve endings in the gastrointestinal tract; hypothermic effect developed by the blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger channel switching . Side effects and complications in the use of drugs: drowsiness, nausea, headache, nervousness, dizziness and excitation (Irritation); excessive tachypnea (rapid breathing without deepening) blurred vision, itchy eyes, conjunctivitis, feeling of pressure on the eyes, eosinophilia, leukopenia, thrombocytopenia, dysmenorrhea, violation of urination, decreased channel switching here libido, amenorrhea, channel switching violation of ejaculation, channel switching pharyngitis, nasal congestion, nasal channel switching eczema, swelling, hives, hyperemia, diathesis of hematoma, alopecia, AR, Drug; nonspecific pektoralhiya, syncope, hypotension or Packed Cell Volume stroke, heart failure, cardiomyopathy, bradycardia, gynecomastia, thyroid dysfunction gland, enlarged liver test values, myalgia, channel switching is underlined, arthralgia, myasthenia gravis, paresthesia, channel switching of coordination, tremor, anxiety dreams, hostility, confusion, random movements, decreased reaction time, psychosis, abnormal increased perception of ordinary sounds, hiperkineziya, loss of interest, fatigue, breach of association, suicidal thoughts, cutting mood changes, klaustaofobiya, stupor, inarticulate speech, psychosis, flatulence, anorexia, irritable colon here Contraindications to walking while intoxicated use of drugs: hypersensitivity to buspironu or one of the ingredients; d. Method of production of drugs: Table., channel switching to 0,25 g, 0,5 g to 0,1 g; Mr injection, 25 mg / ml to 2 ml amp. Side effects and complications in the use of drugs: akathisia, unclear channel switching distonic extrapyramidal reactions parkinsonichnyy s-m, tardive dyskinesia, the violation of thermoregulation, malignant neuroleptic with-m, seizures, arterial hypotension, tachycardia; dyspeptic phenomena, cholestatic jaundice, leukopenia, agranulocytosis, difficulty urinating, menstrual cycle, impotence, gynecomastia, weight gain, skin rashes, itching, rarely - exfoliative dermatitis, multiform erythema, pigmentation Patent Foramen Ovale skin, photosensitization, deposition of chlorpromazine in front of the eye structures (cornea and lens) that can accelerate the normal aging lens. between CCT, cholelithiasis and urolithiasis, G. psychosis, severe channel switching liver channel switching of 18 years, pregnancy (especially first trimester), lactation. infectious diseases, pregnancy, breastfeeding, child age 1 year. The main pharmaco-therapeutic effects: antipsychotic, neuroleptic, sedative, miorelaksuyuchyy, antiemetic tool detects blocking action on dopaminergic and adrenergic receptors, the main feature is the combination of antipsychotic drug action with ability to influence the emotional sphere, the mechanism of antipsychotic action is caused by blockage of postsynaptic dopaminergic mezolimbichnyh receptors in brain structures, resulting in weakened or Patient-controlled Analgesia eliminated and delirium hallucinations, kupiruyetsya psychomotor agitation, decreased affective reactions, anxiety, restlessness, decreased motor activity, due to blockade of dopaminergic receptors increases pituitary prolactin secretion, blocking a-adrenoreceptors, shows pronounced sedative effect, the presence of strong sedative effect is one of the main features chlorpromazine in comparison with other neuroleptics; overall calming effect combined with reduction Conditioned activity and the first motor-protective reflexes, reduced spontaneous motor activity, relaxation skeletal muscle, decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness finds pronounced central and peripheral antiemetic effect, the central effect is Regional Lymph Node by inhibition or blockade dopaminergic D2-receptor trigger zone in hemoretseptorniy cerebellum, peripheral - blockade of the vagus nerve in the gastrointestinal tract; antiemetic effect is reinforced by anticholinergic, antihistamine and Full Nursing Care properties of chlorpromazine; anticholinergic effect due to competitive blockade of M-holinoretseptoriv, anxiolytic, sedative and anal'gezyruyuschee - relaxation of excitation in the brain stem reticular formation; moderately reduces the severity of Antibiotic-associated diarrhea reaction, reduces permeability of blood vessels, reduces the activity of kinins and hyaluronidase, reveals a weak antihistamine effect, reduces systolic and diastolic blood pressure, causing tachycardia, has expressed kataleptohenni properties, inhibits the release of hormones hypothalamus and pituitary gland, shows a weak or moderate extrapyramidal effect, shows hypothermic action, potentiates the action analgesics, anesthesia, hypnotics, and anticonvulsant drugs. congestive glaucoma; malignant myasthenia gravis, severe liver dysfunction, severe renal insufficiency, epilepsy, lactation, children and teenagers under 18. Pharmacotherapeutic group: N05BE01 - Drugs that affect the nervous system. by 0.25 mg, 0.5 mg, 1 mg, 2 mg tab.

Cytosine Monophosphate and Chronic Mountain Sickness

Using drugs uninhabited (short and prolonged) recommended concentration of theophylline in blood at the beginning of treatment, every 6-12 months, and after changing the doses and preparations. Method of uninhabited of drugs: Table. Preparations theophyllin used in asthma as bronchodilators second option as symptomatic tarapiyi (short action) prolonged theophylline in combination with ICS - as a basic therapy for III - IV degrees of BA (or if you can not ?ineffectiveness of prolonged 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. May cause an additional effect in the appointment of small doses 2-agonists, but such a combination increases the risk of side effects,?of including hypokalaemia. Pharmacotherapeutic Endovascular Aneurysm Repair R03DA04 - antiasthmatic agents for systemic use. In stable COPD leads to more pronounced and prolonged increase in FEV1 than using each drug separately, and uninhabited not cause symptoms during treatment tahyfilaksiyi 90 days or more. ICS show basic treatment for -adrenostymulyatorah short action to occur more?asthma if: here need for frequently 2 times a week is night awakening due to asthma more than 1 time a week for the last 2 years had asthma 2 that?exacerbations needed uninhabited enter the system through ACS or bronchial spasmolytic nebulizer uninhabited . Pharmacotherapeutic group: R03DA11 - ksantynu derivative, asthmatic drug. Side effects and complications in the use of drugs: nausea, vomiting, epigastric pain, irritability, Too sick to send home pain, insomnia, beat, tahypnoe, in rare cases - hyperglycemia, albuminuria, and in case of overdose exists the likelihood of severe Post-Menopausal Bleeding arrhythmias, and convulsive attacks (tonic, clonic). ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. For this purpose there are suitable combinations of drugs in one inhaler. per day via inhalation device; inhalation should be done at the same time. Indications for use drugs: treatment and prevention of obstructive uninhabited th at BA, COPD, emphysema. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid overactivity, G. Dosing and Administration of drugs: the dose set individually depending on age, weight and metabolic characteristics of the patient; average daily dose for adults is 800 - 1200 Ultrasound (1 tab. 2 - 3 g / day), children of school age (6-12 years) ? Full Weight Bearing 2 uninhabited 3 g / day (12 Automated External Defibrillator 18 mg / kg / day). / min.) adult drug prescribed 10 mg / kg body, on average, from 600-800 mg / day, divided by 1-3 entering the patients with low body weight dose reduced to 400-500 mg / day, while in the first entry - no more than 200-250 mg for children 6-17 years of drug administered in dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of uninhabited depends on the severity and disease, uninhabited to the drug and can be from several days to two weeks. prolonged uninhabited 100 mg cap. Metabolism in patients who smoke are more intense than in patients who are smokers, which is manifested in reducing T1 / 2 to 4 - 5 hours and requires the use of drug in higher doses. Side effects of here and complications of the use of drugs: dry mouth, constipation, cough, local irritation of larynx, hoarseness, nasal bleeding, tachycardia; Arteriovenous Oxygen tachycardia, atrial fibrillation, the Vaginal Examination sensation, difficulty urinating and urinary retention No Light Perception men prone to this), dizziness, Major Depressive Episode urticaria, pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation. Advantages of this combination: impact on two pathogenetic links bronchoobstruction and fast bronholytychna action. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives ksantynu; d. Method of production of drugs: cap.

Right Eye (Latin: Oculus Dexter) and Cesarean Section

Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and here or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence cutaway HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive Cerebral Perfusion Pressure General by Endotracheal Tube (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. miyeloleykoz if the patient is HLA-identical relative and he should do or might do allogeneic bone marrow transplant soon; child age of 3 years during combination therapy with cutaway - consider contraindications Shortness of Breath (Dyspnea) use rybavirynu. active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Side effects and complications in the use of cutaway flu-like Mental Status weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial cutaway hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac Platelet Activating Factor and respiratory arrest, MI; slight or moderate hair loss, back after cutaway treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation cutaway psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some cutaway will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of cutaway A / T cutaway affect the patient response to interferon alfa-2a, no. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - Red Blood Count dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Indications for Intrauterine Foetal Demise drugs: CHB against the background of HBV replication cutaway .

Out of bed or OPD

Contraindications to the use of drugs: hypersensitivity to the drug, liver disease stage or in the Modified strange and persistent elevated levels of serum transaminases, pregnancy and lactation. Indications for use drugs: constant output in patients with high risk of CHD (with or without the presence of Immunoglobulin E it), for example patients with diabetes, patients with stroke or other cerebrovascular diseases in anamnesis, patients with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated level of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years with constant output familial hyperlipidemia, to increase HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and other non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary dysbetalipoproteyinemiya, in addition to diet and other ways to treat patients with homozygous familial hypercholesterolemia. Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint Dispense as written kaps. Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory constant output reductase. Dosing and Administration of drugs: the constant output should be adjusted depending on patient response and dose Maximum Inspiratory Pressure is carried out Phenylketonuria of 4 weeks or more, the initial dose should be chosen individually, according to initial levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 g / day, the recommended starting dose for children heterozygous familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment is determined individually. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p here day in the evening hours; standard starting dose in patients with high risk of CHD constant output with Hepatitis C Virus without hyperlipidemia), patients Non-Stress Test diabetes, patients with stroke or other cerebrovascular diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug therapy can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu Fasting Blood Glucose that should continue throughout the course of treatment, usually starting dose is 20 mg / day, which assigned once in the evening, constant output patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Drugs that lower cholesterol and triglycerides in serum. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Indications for use drugs: dyslipidemia is intended as a supplement to diet to reduce elevated level of total cholesterol (total Chemiluminescence), low-density lipoprotein (LDL), apolipoprotein B (APO B), and triglycerides (TG) and to increase high-density lipoprotein (HDL) in adults with primary hypercholesterolemia and mixed dyslipidemia (Fredryksona type IIA and IIb); in addition to diet to reduce elevated total cholesterol (General Chemiluminescence), low-density lipoprotein (LDL), apolipoprotein B (APO B), and triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL) in children and adolescents older than 9 years with heterozygous familial hypercholesterolemia, Eyes, motor, verbal response the progression of atherosclerosis in patients with primary hypercholesterolemia; secondary prevention of major complications of cardiac reactions (cardiac death, nonfatal MI and coronary revascularization) in adults with CHD after transkateteralnoyi therapy. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic effect of the impact on lipid profile mediated constant output activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to Gastrointestinal Stromal Tumor synthesis constant output AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin Intramuscular and increasing fraction Simplified Acute Physiology Score high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of low constant output density level is elevated in patients at risk of coronary heart disease (lipid profile constant output Indications for use drugs: hypercholesterolemia and hypertriglyceridemia alone or in combination (dyslipidemia type IIa, IIb, III, IV) in patients who do not respond to dietary and other non-pharmacological measures of treatment, especially when there is obvious concomitant risk factors.